- Home
- BCG vs GLTO Comparison
BCG vs GLTO Comparison
Compare BCG & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- GLTO
- Stock Information
- Founded
- BCG 2016
- GLTO 2011
- Country
- BCG United States
- GLTO Denmark
- Employees
- BCG N/A
- GLTO N/A
- Industry
- BCG
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- GLTO Health Care
- Exchange
- BCG Nasdaq
- GLTO Nasdaq
- Market Cap
- BCG 29.6M
- GLTO 23.7M
- IPO Year
- BCG N/A
- GLTO 2020
- Fundamental
- Price
- BCG $1.47
- GLTO $5.73
- Analyst Decision
- BCG
- GLTO
- Analyst Count
- BCG 0
- GLTO 0
- Target Price
- BCG N/A
- GLTO N/A
- AVG Volume (30 Days)
- BCG 95.8K
- GLTO 767.1K
- Earning Date
- BCG 11-13-2025
- GLTO 11-04-2025
- Dividend Yield
- BCG N/A
- GLTO N/A
- EPS Growth
- BCG N/A
- GLTO N/A
- EPS
- BCG N/A
- GLTO N/A
- Revenue
- BCG $173,961,000.00
- GLTO N/A
- Revenue This Year
- BCG N/A
- GLTO N/A
- Revenue Next Year
- BCG N/A
- GLTO N/A
- P/E Ratio
- BCG N/A
- GLTO N/A
- Revenue Growth
- BCG 7.45
- GLTO N/A
- 52 Week Low
- BCG $1.36
- GLTO $2.01
- 52 Week High
- BCG $6.55
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- BCG 38.43
- GLTO 42.10
- Support Level
- BCG $1.36
- GLTO $7.02
- Resistance Level
- BCG $1.71
- GLTO $7.64
- Average True Range (ATR)
- BCG 0.22
- GLTO 0.58
- MACD
- BCG -0.05
- GLTO -0.55
- Stochastic Oscillator
- BCG 8.59
- GLTO 0.50
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.